Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Emphysema Market Forecast: What Market Value Is Expected By 2030?

The emphysema market, valued at $4.94 billion in 2025, is projected to expand to $5.17 billion by 2026, reflecting a compound annual growth rate of 4.6%. This anticipated expansion builds upon a foundation of historical growth drivers, including the widespread prevalence of smoking, increased exposure to environmental pollutants, an aging global demographic, heightened awareness surrounding respiratory ailments, and broader access to healthcare services.

The emphysema market is projected for consistent expansion in the coming years, anticipating a substantial increase to $6.19 billion by the year 2030, driven by a compound annual growth rate of 4.6%. This upward trajectory in the forecast period is anticipated to be fueled by several key factors, including proactive early screening programs, the increasing implementation of respiratory care within home settings, the wider adoption of sophisticated diagnostic tools, a heightened emphasis on managing chronic conditions, and the enforcement of environmental health regulations. Furthermore, prominent trends shaping this market during the forecast period encompass the rising incidence of chronic respiratory ailments, a greater concentration on the early identification of COPD, an expansion in the provision of long-term oxygen therapy, a broader rollout of pulmonary rehabilitation initiatives, and a strengthened focus on strategies aimed at smoking cessation.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21956&type=smp

Emphysema Market Growth Drivers And Industry Catalysts

The upward trend in respiratory infections is anticipated to be a significant catalyst for the expansion of the emphysema market. Such infections, which impact the respiratory organs like the sinuses, throat, airways, and lungs, are on the rise due to factors such as environmental pollution, climate shifts, microbial resistance, increasing urbanization, and the emergence of new pathogens. These infections exacerbate the progression of emphysema by inducing inflammation, causing tissue damage, and leading to greater airway blockage, ultimately diminishing lung capacity. A relevant illustration is the data from November 2024 provided by the Centers for Disease Control and Prevention, which indicated that in 2023, the United States recorded 9,633 cases of tuberculosis (TB), marking a 15.6% increase from the 8,332 cases in 2022, with the rate of incidence climbing by 15.0% from 2.5 to 2.9 per 100,000 individuals, thereby underscoring how the growing incidence of respiratory ailments is fueling the development of the emphysema market.

Emphysema Market Segment Analysis And Revenue Opportunities

The emphysema market covered in this report is segmented –

1) By Type: Centrilobular, Panlobular

2) By Treatment: Medication, Therapy, Surgery, Other Treatments

3) By Diagnosis: Imaging Test, Lung Function Test, Other Diagnosis

4) By Complications: Chest Infections, Collapsed Lung, Heart Problems, Lungs Hole, Other Complications

5) By End-User: Hospitals And Clinics, Surgical Center, Other End-Users

Subsegments:

1) By Centrilobular: Mild Centrilobular Emphysema, Moderate Centrilobular Emphysema, Severe Centrilobular Emphysema

2) By Panlobular: Mild Panlobular Emphysema, Moderate Panlobular Emphysema, Severe Panlobular Emphysema

#Emphysema Market Trends Influencing Long-Term Demand

In the realm of emphysema treatment, leading pharmaceutical firms are prioritizing the development of groundbreaking medical advancements. These innovations, like inhaled dual inhibitors targeting phosphodiesterase 3 and phosphodiesterase 4, aim to furnish patients with sophisticated therapies designed to elevate lung capacity, assuage inflammation, and generally improve the comprehensive handling of the ailment, ultimately contributing to enhanced respiratory well-being and a superior quality of life. Such a dual inhibitor functions by specifically addressing and obstructing two key phosphodiesterase enzymes within the pulmonary system, leading to the relaxation of respiratory passages and a decrease in inflammatory responses, thereby facilitating easier respiration for individuals suffering from conditions like chronic obstructive pulmonary disease. A notable development occurred in June 2024 when Verona Pharma plc, a pharmaceutical entity based in the United Kingdom, introduced Ohtuvayre (ensifentrine). This groundbreaking medication, which gained approval from the U.S. Food and Drug Administration, stands as the premier inhaled dual PDE3 and PDE4 inhibitor authorized for the ongoing management of chronic obstructive pulmonary diseases, including emphysema, signifying the advent of a novel inhaled therapeutic approach after more than two decades. This medication, which synergistically offers both bronchodilatory and anti-inflammatory benefits, is slated for distribution via specialized pharmaceutical outlets.

Emphysema Market Leading Players Shaping Industry Direction

Major companies operating in the emphysema market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., AstraZeneca PLC, Novartis International AG, GlaxoSmithKline PLC, Koninklijke Philips N.V., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Mylan N.V., ResMed Inc., Chiesi Farmaceutici S.p.A., VIDA Diagnostics Inc., Pulmonx Corporation, F Hoffmann‑La Roche Ltd, Cipla Limited, Abbott Laboratories, Astellas Pharma Inc., Covis Pharma Group, FindAir Sp z o o, Arrowhead Pharmaceuticals, Regeneron Pharmaceuticals, Zydus Lifesciences, Theravance Biopharma Inc, Pulmatrix Inc, Genentech, Dimerix Ltd, InMed Pharmaceuticals Inc.

Access The Complete Emphysema Market Report:

https://www.thebusinessresearchcompany.com/report/emphysema-global-market-report

Emphysema Market Regional Analysis And Leading Geography

North Americawas the largest region in the emphysema market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the emphysema market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model